Beam Therapeutics Inc.
BEAM
$26.75
$0.240.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 158.88% | 157.97% | 120.01% | -84.07% | -82.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 158.88% | 157.97% | 120.01% | -84.07% | -82.90% |
| Cost of Revenue | 3.13% | 8.85% | 11.44% | 1.38% | -3.81% |
| Gross Profit | 24.81% | 20.97% | 11.24% | -529.67% | -465.48% |
| SG&A Expenses | 14.02% | 6.71% | 2.06% | -12.63% | -12.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.49% | 8.36% | 9.26% | -1.94% | -5.73% |
| Operating Income | 15.24% | 13.72% | 7.67% | -155.26% | -141.81% |
| Income Before Tax | 78.51% | 83.21% | 79.06% | -190.85% | -180.70% |
| Income Tax Expenses | -- | -- | -- | -100.00% | -100.00% |
| Earnings from Continuing Operations | 78.51% | 83.21% | 79.06% | -188.01% | -177.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 78.51% | 83.21% | 79.06% | -188.01% | -177.94% |
| EBIT | 15.24% | 13.72% | 7.67% | -155.26% | -141.81% |
| EBITDA | 16.09% | 14.55% | 8.19% | -176.20% | -160.31% |
| EPS Basic | 81.91% | 86.11% | 79.09% | -157.00% | -154.94% |
| Normalized Basic EPS | 81.27% | 84.30% | 77.62% | -183.83% | -183.09% |
| EPS Diluted | 80.87% | 85.10% | 78.08% | -150.95% | -149.08% |
| Normalized Diluted EPS | 80.21% | 83.24% | 76.55% | -176.90% | -176.19% |
| Average Basic Shares Outstanding | 16.28% | 22.41% | 20.10% | 14.69% | 9.67% |
| Average Diluted Shares Outstanding | 16.86% | 23.02% | 20.72% | 14.05% | 9.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |